Prognostic Value of NETosis Markers for Thrombosis During Myeloproliferative Neoplasms (AVATARE)
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity Hospital, Bordeaux
About this trial
Myeloproliferative neoplasms are hematologic diseases characterized by an increased proliferation of peripheral blood cells. The main risk of MPN is the occurrence of thrombosis. Thrombosis risk is mainly evaluated using two criteria: age and prior thrombosis. A better prediction of thrombosis risk is needed to improve prevention and treatment of MPN-associated thrombosis. The objective of the study is to evaluate the predictive value of neutrophil extracellular traps markers in thrombosis during MPN.
Eligibility criteria
Qualifiers
Diagnosis of Polycythemia Vera (PV), Essential Thrombocythemia (ET), or pre-myelofibrosis (pre-MF)
JAK2V617F mutation with an allelic burden greater than 1%
High risk of thrombosis (age over 60 years or prior thrombotic event)
Diagnosis of MPN within the last 12 months
Disqualifiers
Severe hepatic or renal insufficiency (Creatinine clearance <30ml/min)
Patients under legal protection (guardianship or curatorship)
Patients under heparin treatment at inclusion
Trial design
Treatments tested in this trial
- Additional blood sampling
Treatment groups
300 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov